Orthobiologics Global Market Report 2024

The orthobiologics market size has grown strongly in recent years. It will grow from $6.65 billion in 2023 to $7.08 billion in 2024 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to several factors, including the rise in the prevalence of orthopedic diseases and conditions, a shift towards minimally invasive procedures, an increase in the number of reconstructive surgeries, higher healthcare expenditure, increased awareness among patients and healthcare providers, and economic development in emerging markets.

The orthobiologics market size is expected to see strong growth in the next few years. It will grow to $9.12 billion in 2028 at a compound annual growth rate (CAGR) of 6.5%. The growth in the forecast period can be attributed to factors such as the aging population and sedentary lifestyles, ongoing development of advanced products, favorable reimbursement policies, regulatory approvals for new orthobiologic products, and expanded indications for existing orthobiologic products. Major trends in the forecast period include advancements in regenerative medicine, product innovations, technological advancements, strategic initiatives, and market expansion.

The orthobiologics market is poised for growth due to the increasing incidence of road accidents and sports injuries, which often result in musculoskeletal damage. These incidents are fueled by various factors such as distracted driving, speeding, unfavorable road conditions, overuse, inadequate equipment, and insufficient sports injury prevention measures. Orthobiologics play a crucial role in treating such injuries by facilitating faster and more effective healing of musculoskeletal tissues, reducing inflammation, and enhancing the body's natural repair processes. This is achieved through the application of substances such as bone grafts, growth factors, stem cells, and platelet-rich plasma. For example, in May 2022, the National Highway Traffic Safety Administration reported a 10.5% increase in motor vehicle crash fatalities in 2021, reaching approximately 42,915 deaths compared to 38,824 in 2020, indicating the growing demand for orthobiologics in addressing injuries from road accidents and sports.

Key players in the orthobiologics market are actively developing advanced solutions to improve bone healing and fusion in orthopedic procedures. Dry allograft mixtures, for instance, combine sturdy cortical fibers with mineralized cortical bone, offering structural support and promoting osteoinductive properties for new bone formation. Isto Biologics, a US-based biologics-focused company, introduced Fibrant Liberty allograft in May 2024, featuring robust cortical fibers integrated with mineralized cortical cancellous chips. This graft, upon hydration, becomes pliable and can be tailored for various surgical procedures. Its longer and stronger fibers improve handling and form a network that prevents graft migration while maintaining structural integrity.

In February 2023, Zimmer Biomet Holdings Inc., a US-based medical technology company, completed the acquisition of Embody Inc. for $155 million. This strategic move underscores Zimmer's commitment to investing in areas with significant growth potential and introducing innovations to benefit patients and surgeons. Embody, a US-based soft tissue healing company, specializes in developing and manufacturing collagen-based biologic products for soft tissue augmentation and repair. The acquisition includes Embody's comprehensive portfolio of collagen-based biointegrative solutions aimed at supporting healing in challenging orthopedic soft tissue injuries.

Major companies operating in the orthobiologics market are Johnson & Johnson, Medtronic plc, Zimmer Biomet, Arthrex Inc., Integra Lifesciences Corporation, NuVasive Inc., Globus Medical, Bioventus, MTF Biologics, ATEC Spine Inc., Exactech Inc., SeaSpine, RTI Surgical, AlloSource, XTANT MEDICAL, Spine Wave Inc., Bone Biologics Corp., Locate Bio Limited, Wright Medical Group N.V., BoneSupport AB, Graftys, Regenexx, Acumed LLC, Baxter International Inc., LifeNet Health.

North America was the largest region in the orthobiologics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the orthobiologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the orthobiologics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Orthobiologics refer to therapies derived from natural substances utilized in treating various musculoskeletal conditions. These therapies aim to enhance the body's capacity to repair and regenerate bones, cartilage, tendons, and ligaments in orthopedic treatments, ultimately improving recovery times and outcomes in procedures such as spinal fusion, fracture repair, and joint reconstruction.

The main products of orthobiologics include viscosupplements, bone growth factors, demineralized bone matrix, synthetic bone substitutes, cellular allografts, and others. Viscosupplements are gel-like substances injected into joints to provide lubrication and cushioning, thereby reducing pain and enhancing mobility in individuals with osteoarthritis. These products find applications across various fields, including spinal fusion, maxillofacial and dental surgeries, soft tissue repair, reconstructive and fracture surgery, and others. They are utilized by various end users such as hospitals, orthopedic clinics, ambulatory surgery centers, and others.

The orthobiologics market research report is one of a series of new reports that provides orthobiologics market statistics, including the orthobiologics industry global market size, regional shares, competitors with orthobiologics market share, detailed orthobiologics market segments, market trends, and opportunities, and any further data you may need to thrive in the orthobiologics industry. These orthobiologics market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The orthobiologics market consists of sales of bone morphogenetic proteins, hyaluronic acid, stem cells, and platelet-rich plasma. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.